Boston Trust Walden Corp Has $358,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

Boston Trust Walden Corp lowered its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 11.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,471 shares of the company’s stock after selling 695 shares during the period. Boston Trust Walden Corp’s holdings in AstraZeneca were worth $358,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. McClarren Financial Advisors Inc. boosted its position in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in AstraZeneca during the third quarter valued at approximately $28,000. Albion Financial Group UT boosted its holdings in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after purchasing an additional 248 shares in the last quarter. Groupama Asset Managment grew its stake in shares of AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after purchasing an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in shares of AstraZeneca in the 3rd quarter worth approximately $45,000. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the topic of a number of analyst reports. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Price Performance

Shares of AZN stock opened at $68.96 on Wednesday. The stock’s fifty day moving average is $67.15 and its 200-day moving average is $73.79. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The stock has a market capitalization of $213.85 billion, a PE ratio of 33.00, a PEG ratio of 1.18 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the company posted $0.87 EPS. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. Equities research analysts expect that AstraZeneca PLC will post 4.13 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.